Kimberly-Clark is set to acquire Kenvue, the maker of Tylenol, in a deal worth around $48.7 billion that combines both cash and stock. This merger will lead to the formation of a substantial consumer health products entity.
Shareholders of Kimberly-Clark will hold about 54% of the newly formed company, while Kenvue investors will own roughly 46%.
The united company will encompass a wide range of well-known household brands, merging Kenvue’s Listerine and Band-Aids with Kimberly-Clark’s Cottonelle, Huggies, and Kleenex. The combined entity will also generate about $32 billion in annual revenue.
Kenvue has been an independent player for only a couple of years, having been spun off from Johnson & Johnson in 2021. The decision to separate its Consumer Health division from other sectors was made at the end of that year.
This acquisition, announced on a Monday, is one of the major purchases of the year.
Last month, Kenvue attracted significant media interest when Secretary of Health and Human Services Robert F. Kennedy Jr. reiterated unfounded claims linking Tylenol to autism, implying that opposition to his stance stemmed from anti-Trump sentiments.
Kennedy reiterated his claims in discussions with President Trump and others, despite acknowledging the lack of scientific backing.
In July, Kenvue revealed that CEO Thibault Mongon would depart due to pressure from activist investors and an ongoing strategic assessment. Board member Kirk Perry will step in as interim CEO.
“We cater to billions of consumers throughout their lives,” stated Mike Hsu, Chairman and CEO of Kimberly-Clark.
Hsu will take on the roles of chairman and CEO in the new company, with three of Kenvue’s board members joining Kimberly-Clark’s board once the deal closes. The headquarters in Irving, Texas, will remain with Kimberly-Clark, alongside a substantial presence in Kenvue’s location.
The transaction is anticipated to finalize in the latter half of the upcoming year, pending approval from the shareholders of both companies.
At the closing of the deal, Kenvue shareholders will receive $3.50 in cash per share and 0.14625 shares of Kimberly-Clark for every Kenvue share they own. This totals approximately $21.01 per share based on Kimberly-Clark’s stock price from the previous Friday.
Both companies have projected potential cost savings of about $1.9 billion in the first three years following the merger.
Following the announcement, Kimberly-Clark’s stock saw a decline of over 15% in premarket trading, while Kenvue experienced an increase of more than 20% in its stock price.
